Edesa Biotech is trading at $5.86 (+9.44%) with no new company-specific announcement dated August 17, 2026 identified.
- The latest reported update, on August 13, described Phase 2 EB06 vitiligo-site activation and recruitment expected in coming weeks.
- The update also highlighted serious liquidity concerns.
- Broader markets are nearly flat and do not clearly explain the move.